Form 8-K - Current report:
SEC Accession No. 0001193125-24-159994
Filing Date
2024-06-12
Accepted
2024-06-12 16:41:02
Documents
15
Period of Report
2024-06-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d839370d8k.htm   iXBRL 8-K 57240
2 EX-10.1 d839370dex101.htm EX-10.1 65987
6 GRAPHIC g839370g0612083357697.jpg GRAPHIC 4630
  Complete submission text file 0001193125-24-159994.txt   281078

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA elym-20240612.xsd EX-101.SCH 2839
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE elym-20240612_lab.xml EX-101.LAB 17979
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE elym-20240612_pre.xml EX-101.PRE 11251
18 EXTRACTED XBRL INSTANCE DOCUMENT d839370d8k_htm.xml XML 3651
Mailing Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808
Business Address 2801 CENTERVILLE ROAD 1ST FLOOR PMB #117 WILMINGTON DE 19808 877-354-3689
Eliem Therapeutics, Inc. (Filer) CIK: 0001768446 (see all company filings)

EIN.: 832273741 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40708 | Film No.: 241038936
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)